Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet?

References

• SEER: surveilance EaERP. Cancer StatFacts: acute lymphocytic leukemia (ALL). 2023. https://seer.cancer.gov/statfacts/html/alyl.html
   Google Scholar
• Sasaki K, Jabbour E, Short NJ, et al. Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol. 2021; 96(6):650–658. doi:10.1002/ajh.26156
   PubMed Web of Science ®Google Scholar
• Geyer MB, Hsu M, Devlin SM, et al. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood. 2017;129(13):1878–1881. doi:10.1182/blood-2016-11-749507
   PubMed Web of Science ®Google Scholar
• Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 2012; 26(3):123–135. doi:10.1016/j.blre.2012.01.001
   PubMed Web of Science ®Google Scholar
• Roberts KG, Gu Z, Payne-Turner D, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394–401. doi:10.1200/JCO.2016.69.0073
   PubMed Web of Science ®Google Scholar
• Moorman AV, Chilton L, Wilkinson J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115(2):206–214. doi:10.1182/blood-2009-07-232124
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Vitale A, Cazzaniga G, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98(11):1702–1710. doi:10.3324/haematol.2012.080432
   PubMed Web of Science ®Google Scholar
• Stengel A, Schnittger S, Weissmann S, et al. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014; 124(2):251–258. doi:10.1182/blood-2014-02-558833
   PubMed Web of Science ®Google Scholar
• Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548–1559. doi:10.1182/blood-2018-10-881961
   PubMed Web of Science ®Google Scholar
• Siegel SE, Stock W, Johnson RH, et al. Pediatric-Inspired treatment regimens for adolescents and young adults with Philadelphia Chromosome-Negative acute lymphoblastic leukemia: a review. JAMA Oncol. 2018; 4(5):725–734. doi:10.1001/jamaoncol.2017.5305
   PubMed Web of Science ®Google Scholar
• Advani AS, Larsen E, Laumann K, et al. Comparison of CALGB 10403 (alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021; 5(2):504–512. doi:10.1182/bloodadvances.2020002439
   PubMed Web of Science ®Google Scholar
• Patel B, Kirkwood AA, Dey A, et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017; 31(1):58–64. doi:10.1038/leu.2016.219
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016; 96(4):375–380. doi:10.1111/ejh.12600
   PubMed Web of Science ®Google Scholar
• Sancho JM, Ribera JM, Xicoy B, et al. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2007; 78(2):102–110. doi:10.1111/j.1600-0609.2006.00778.x
   PubMed Web of Science ®Google Scholar
• Williams GR, Mackenzie A, Magnuson A, et al. Comorbidity in older adults with cancer. J Geriatr Oncol. 2016;7(4):249–257. doi:10.1016/j.jgo.2015.12.002
   PubMed Web of Science ®Google Scholar
• Omura GA, Moffitt S, Vogler WR, et al. Combination chemotherapy of adult acute lymphoblastic leukemia with randomized Central nervous system prophylaxis. Blood. 1980; 55(2):199–204. doi:10.1182/blood.V55.2.199.199
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for Central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86(6):2091–2097. doi:10.1182/blood.V86.6.2091.bloodjournal8662091
   PubMed Web of Science ®Google Scholar
• O'Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113(8):2097–2101. doi:10.1002/cncr.23819
   PubMed Web of Science ®Google Scholar
• Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157(4):463–471. doi:10.1111/j.1365-2141.2012.09095.x
   PubMed Web of Science ®Google Scholar
• Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92(5):1556–1564.
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Leguay T, Thomas X, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica. 2011;96(2):245–252. doi:10.3324/haematol.2010.027862
   PubMed Web of Science ®Google Scholar
• Flannelly C, Tan BE, Tan JL, et al. Barriers to hematopoietic cell transplantation for adults in the United States: a systematic review with a focus on age. Biol Blood Marrow Transplant. 2020; 26(12):2335–2345. doi:10.1016/j.bbmt.2020.09.013
   PubMed Web of Science ®Google Scholar
• Mei M, Tsai NC, Mokhtari S, et al. Long-Term outcomes of allogeneic hematopoietic cell transplant with fludarabine and melphalan conditioning and tacrolimus/sirolimus as graft-versus-Host disease prophylaxis in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2020;26(8):1425–1432. doi:10.1016/j.bbmt.2020.04.015
   PubMed Web of Science ®Google Scholar
• Rosko AE, Wang HL, de Lima M, et al. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol. 2017; 92(1):42–49. doi:10.1002/ajh.24575
   PubMed Web of Science ®Google Scholar
• Roth-Guepin G, Canaani J, Ruggeri A, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. Oncotarget. 2017;8(68):112972–112979. doi:10.18632/oncotarget.22934
   PubMedGoogle Scholar
• Sijs-Szabo A, Dinmohamed AG, Versluis J, et al. Allogeneic stem cell transplantation in patients >40 years of age with acute lymphoblastic leukemia: reduced intensity versus myeloablative conditioning. Transplantation. 2023;107(12):2561–2567. doi:10.1097/TP.0000000000004706
   PubMed Web of Science ®Google Scholar
• Ram R, Storb R, Sandmaier BM, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011;96(8):1113–1120. doi:10.3324/haematol.2011.040261
   PubMed Web of Science ®Google Scholar
• Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the bone marrow transplant survivor study. Blood. 2006;108(8):2867–2873. doi:10.1182/blood-2006-02-003954
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim HT, Ho VT, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38(4):305–310. doi:10.1038/sj.bmt.1705434
   PubMed Web of Science ®Google Scholar
• Advani AS, Moseley A, O'Dwyer KM, et al. SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia Chromosome-Negative B-cell acute lymphoblastic leukemia. J Clin Oncol. 2022; 40(14):1574–1582. doi:10.1200/JCO.21.01766
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Senapati J, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023; 10(6):e433–e444. doi:10.1016/S2352-3026(23)00073-X
   PubMed Web of Science ®Google Scholar
• Jabbour E, Aldoss I, Fleming S, et al. Blinatumomab alternating with low-intensity chemotherapy (CT) treatment for older adults with newly diagnosed Philadelphia (Ph)-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is well tolerated and efficacious: Safety Run-In results for the phase 3 randomized controlled golden gate study. Blood. 2022;140(Supplement 1):6134–6136. doi:10.1182/blood-2022-156080
   Google Scholar
• Chevallier P, Leguay T, Kim R, et al. Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL): results of the EWALL-INO study. Blood. 2022;140(Supplement 1):6114–6116. doi:10.1182/blood-2022-166035
   Google Scholar
• Stelljes M, Alakel N, Wäsch R, et al. Inotuzumab ozogamicin induction followed by standard chemotherapy yields high remission rates and promising survival in older (>55 years) patients with De novo B-Lymphoblastic leukemia (GMALL-Initial1 trial). Blood. 2022;140(Supplement 1):510–512. doi:10.1182/blood-2022-162235
   Google Scholar
• Aldoss I, Otoukesh S, Zhang J, et al. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer. 2021;128(3):529–535. Oct 11. doi:10.1002/cncr.33967
   PubMed Web of Science ®Google Scholar
• Litzow MR, Sun Z, Paietta E, et al. Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-Lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III national cooperative clinical trials network trial. Blood. 2022;140(Supplement 2):LBA-1–LBA-1. doi:10.1182/blood-2022-171751
   Google Scholar
• Litzow M, Sun Z, Mattison R, et al. S115: consolidation with blinatumomab improves overall and relapse-free survival in patients with newly diagnosed B-cell acute lymphoblastic leukemia: impact of age and mrd level in ecog-acrin e1910. HemaSphere. 2023;7(S3):e1944062. doi:10.1097/01.HS9.0000967372.19440.62
   Google Scholar
• Haddad F, Kantarjian H, Short N, et al. P355: mini-hyper-cvd plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed B-cell acute lymphoblastic leukemia: updates from a phase II trial. HemaSphere. 2022;6:255–256. doi:10.1097/01.HS9.0000844308.97537.9c
   Google Scholar
• Short NJ, Kantarjian HM, Ravandi F, et al. Reduced-Intensity chemotherapy with mini-Hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed Philadelphia Chromosome-Negative acute lymphoblastic leukemia: results from a phase II study. Blood. 2020;136(Supplement 1):15–17. doi:10.1182/blood-2020-138569
   Google Scholar
• Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; Aug 7398(10299):491–502. doi:10.1016/S0140-6736(21)01222-8
   PubMed Web of Science ®Google Scholar
• Aldoss I, Khaled SK, Wang X, et al. Favorable activity and safety profile of memory-enriched CD19-Targeted chimeric antigen receptor T cell therapy in adults with high-risk relapsed/refractory ALL. Clin Cancer Res. 2022;29(4):742–753. Oct 18. doi:10.1158/1078-0432.CCR-22-2038
   Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-Term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–459. doi:10.1056/NEJMoa1709919
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528. doi:10.1016/S0140-6736(14)61403-3
   PubMed Web of Science ®Google Scholar
• Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–3331. doi:10.1182/blood-2017-02-769208
   PubMed Web of Science ®Google Scholar
• Myers RM, Taraseviciute A, Steinberg SM, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022;40(9):932–944. doi:10.1200/JCO.21.01405
   PubMed Web of Science ®Google Scholar
• O'Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142–1146. doi:10.1158/1078-0432.CCR-18-2035
   PubMed Web of Science ®Google Scholar
• Bouchkouj N, Lin X, Wang X, et al. FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Oncologist. 2022;27(10):892–899. doi:10.1093/oncolo/oyac163
   PubMed Web of Science ®Google Scholar
• Laetsch TW, Maude SL, Rives S, et al. Three-Year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664–1669. doi:10.1200/JCO.22.00642
   PubMed Web of Science ®Google Scholar
• Shah BD, Ghobadi A, Oluwole OO, et al. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol. 2022; 15(1):170. doi:10.1186/s13045-022-01379-0
   PubMed Web of Science ®Google Scholar
• Qi Y, Zhao M, Hu Y, et al. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022;139(23):3376–3386. doi:10.1182/blood.2021013733
   PubMed Web of Science ®Google Scholar
• Schultz LM, Baggott C, Prabhu S, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric Real-World chimeric antigen receptor consortium report. J Clin Oncol. 2022;40(9):945–955. doi:10.1200/JCO.20.03585
   PubMed Web of Science ®Google Scholar
• Morris EC, Neelapu SS, Giavridis T, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85–96. doi:10.1038/s41577-021-00547-6
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• Dubnikov Sharon T, Assayag M, Avni B, et al. Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma. Br J Haematol. 2023;202(1):74–85. doi:10.1111/bjh.18816
   PubMed Web of Science ®Google Scholar
• Garfall AL, Dancy EK, Cohen AD, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812–2815. doi:10.1182/bloodadvances.2019000600
   PubMed Web of Science ®Google Scholar
• Shah BD, Cassaday RD, Park JH, et al. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023;11(8):e007118. doi:10.1136/jitc-2023-007118
   PubMed Web of Science ®Google Scholar
• Hay KA, Gauthier J, Hirayama AV, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019; 133(15):1652–1663. doi:10.1182/blood-2018-11-883710
   PubMed Web of Science ®Google Scholar
• Li M, Xue S-L, Tang X, et al. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. Sci Rep. 2022;12(1):378. doi:10.1038/s41598-021-04296-3
   PubMed Web of Science ®Google Scholar
• Yan Z, Zhang H, Cao J, et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment [original research]. Front Immunol. 2021;12:611366. 2021-February-23;12. doi:10.3389/fimmu.2021.611366
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–2138. doi:10.1172/JCI85309
   PubMed Web of Science ®Google Scholar
• Leahy AB, Newman H, Li Y, et al. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021; 8(10):e711–e722. doi:10.1016/S2352-3026(21)00238-6
   PubMed Web of Science ®Google Scholar
• Jacoby E, Bielorai B, Avigdor A, et al. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am J Hematol. 2018;93(12):1485–1492. doi:10.1002/ajh.25274
   PubMed Web of Science ®Google Scholar
• Chen LY, Gong WJ, Li MH, et al. Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph + acute lymphoblastic leukemia. Blood Adv. 2023; 7(17):4913–4925. doi:10.1182/bloodadvances.2022009072
   PubMed Web of Science ®Google Scholar
• Yin Z, Lin Y, Liu D, et al. CAR-T therapy as a consolidation in remission B-ALL patients with poor prognosis. Cancer Rep (Hoboken). 2022;5(10):e1706.
   PubMedGoogle Scholar
• Myers RM, Li Y, Barz Leahy A, et al. Humanized CD19-Targeted chimeric antigen receptor (CAR) T cells in CAR-Naive and CAR-Exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol. 2021;39(27):3044–3055. doi:10.1200/JCO.20.03458
   PubMed Web of Science ®Google Scholar
• Brudno JN, Lam N, Vanasse D, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270–280. doi:10.1038/s41591-019-0737-3
   PubMed Web of Science ®Google Scholar
• Khan AN, Chowdhury A, Karulkar A, et al. Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation. Front Immunol. 2022;13:886546. doi:10.3389/fimmu.2022.886546
   PubMed Web of Science ®Google Scholar
• Wang X, Diamond DJ, Forman SJ, et al. Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. Int J Hematol. 2021; 114(5):544–553. doi:10.1007/s12185-021-03215-6
   PubMed Web of Science ®Google Scholar
• Aldoss I, La Rosa C, Baden LR, et al. Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial. Ann Intern Med. 2020;172(5):306–316. doi:10.7326/M19-2511
   PubMed Web of Science ®Google Scholar